02 July 2004
Med Sci Monit 2004; 10(7): RA155-165 :: ID: 11708
Although at present, highly active antiretroviral therapy (HAART) has greatly reduced the number of viral copies to an undetectable level and has slowed down the progress of the disease in patients with human immunodeficiency virus (HIV) infection, the HIV-infected cells are not eradicated by this therapy. Virus replication rebounds once the drug therapy is terminated, regardless of duration of the therapy, primarily due to the establishment of a viral reservoir. Therefore, viral suppressive therapy is a lifelong task and may be accompanied by many as yet unidentified serious side effects. In addition, the maximum therapeutic benefits of HAART appear to have been reached recently in the U. S, and the incidences of multi-drug resistant viral strain infections are slowly but steadily increasing. Without an effective vaccine, which has already proved to be very difficult to develop, for the protection of the uninfected population and a feasible eradication strategy to cure infected patients, the number of HIV-infected persons will inevitably continue to rise. While the vast majority of endeavors are focused on developing new drugs that target different steps of HIV replication for suppressive therapy, researchers need to find a therapeutic strategy that directly aims at HIV-infected cells to cure the disease. In this article, I review and discuss some potential approaches to eradicate HIV-infected cells from the patients.
Keywords: Anti-HIV Agents - therapeutic use, Antiretroviral Therapy, Highly Active, Bone Marrow Transplantation - immunology, Clinical Trials, Gene Therapy, HIV - physiology, HIV Infections - immunology, HIV Infections - therapy, HIV Infections - virology, Immunotoxins - pharmacology, Immunotoxins - therapeutic use, RNA, Small Interfering - pharmacology, RNA, Small Interfering - therapeutic use, T-Lymphocytes, Cytotoxic - immunology, Transplantation, Homologous, Virus Latency - drug effects, Virus Latency - physiology, Virus Replication - drug effects, Virus Replication - physiology, Anti-HIV Agents - therapeutic use, Antiretroviral Therapy, Highly Active, Bone Marrow Transplantation - immunology, Clinical Trials as Topic, genetic therapy, HIV - physiology, HIV Infections - virology, Immunotoxins - therapeutic use, RNA, Small Interfering - therapeutic use, T-Lymphocytes, Cytotoxic - immunology, Transplantation, Homologous, Virus Latency - physiology, Virus Replication - physiology
01 August 2022 : EditorialEditorial: Long-Term Effects of Symptomatic and Asymptomatic SARS-CoV-2 Infection in Children and the Changing Pathogenesis of Common Childhood Viruses Driven by the COVID-19 Pandemic
Med Sci Monit 2022; 28:e937927
08 Aug 2022 : Clinical ResearchA 3-Year Clinical Evaluation of Endodontically Treated Posterior Teeth Restored with Resin Nanoceramic Comp...
Med Sci Monit In Press; DOI: 10.12659/MSM.937331
08 Aug 2022 : Clinical ResearchHemoglobin/Red Blood Cell Distribution Width Ratio in Peripheral Blood Is Positively Associated with Progno...
Med Sci Monit In Press; DOI: 10.12659/MSM.937146
05 Aug 2022 : Clinical ResearchA Retrospective Study of 98 Elderly Patients with High-Risk Lateral Femoral Wall Intertrochanteric Hip Frac...
Med Sci Monit In Press; DOI: 10.12659/MSM.936923
Most Viewed Current Articles
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292